Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This molecule is an uncharacterized natural antisense transcript (lncRNA) identified in the human genome and mapped antisense to the PSMD8 locus. Natural antisense transcripts are a widespread and diverse class of non-coding RNAs transcribed from the DNA strand opposite to protein-coding or non-coding sense genes. Across the genome, such antisense RNAs have been shown in some cases to modulate the expression of their sense counterpart through various mechanisms, including transcriptional collision, chromatin modification, and RNA masking, but the function of most antisense transcripts—including this one—is not well established[7]. The underlying sense gene, PSMD8 (Proteasome 26S Subunit, Non-ATPase 8), encodes a component of the 26S proteasome involved in ATP-dependent degradation of ubiquitinated proteins[1][3][6]. While PSMD8 is involved in cell cycle control, apoptosis, and has disease relevance, there is currently no evidence that this specific antisense transcript ("novel transcript, antisense to PSMD8") is a therapeutic target, disease biomarker, or has any known drug interactions. No protein product is encoded, and no canonical gene symbol beyond the Ensembl designation (ENSG00000294383) has been established. This antisense transcript should not be considered a druggable target or a canonical protein/receptor of pharmaceutical interest[7][5]. Further research would be needed to characterize its potential biological functions and relevance. Notes: - The entry is likely not misspelled, but by current knowledge, it refers to a non-protein-coding transcript with unproven function and is not considered a therapeutic target. - PSMD8, the sense gene, is a well-characterized proteasome subunit relevant in disease, but this "novel transcript, antisense to PSMD8" is a distinct non-coding RNA with limited annotation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to PSMD8 (ENSG00000294383).